Why the study?
Does cyclophosphamide treatment increase the incidence of persistent CNS enterovirus infections and late paralysis in mice inoculated with attenuated human poliovirus?
Population
Mice inoculated intracerebrally with attenuated human poliovirus
Comparison
Cyclophosphamide (CY) treatment vs No cyclophosphamide treatment
Design
Preclinical
Follow-up
Up to 146 days
Authors
Loading...
CY immunosuppression increases clinical disease in poliovirus-inoculated mice; leaves open relevance to persistent human enterovirus infections.
Does cyclophosphamide treatment increase the incidence of persistent CNS enterovirus infections and late paralysis in mice inoculated with attenuated human poliovirus?
Cyclophosphamide treatment in mice inoculated with attenuated poliovirus serves as a model for persistent CNS enterovirus infections, leading to late paralysis and suppressed immune responses.
Jubelt et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: